Sumitomo Mitsui Trust Group
NBIX icon

Sumitomo Mitsui Trust Group’s Neurocrine Biosciences NBIX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3M Sell
215,488
-4,961
-2% -$736K 0.02% 533
2026
Q1 		$29M Buy
220,449
+17,783
+9% +$2.36M 0.02% 570
2025
Q4 		$28.7M Sell
202,666
-18,624
-8% -$2.7M 0.02% 590
2025
Q3 		$31.1M Sell
221,290
-14,198
-6% -$1.92M 0.02% 584
2025
Q2 		$29.6M Buy
235,488
+4,030
+2% +$462K 0.02% 585
2025
Q1 		$25.6M Sell
231,458
-1,399
-0.6% -$177K 0.02% 602
2024
Q4 		$31.8M Buy
232,857
+916
+0.4% +$113K 0.02% 569
2024
Q3 		$26.7M Sell
231,941
-11,502
-5% -$1.58M 0.02% 598
2024
Q2 		$33.5M Sell
243,443
-9,122
-4% -$1.25M 0.02% 527
2024
Q1 		$34.8M Buy
252,565
+8,630
+4% +$1.18M 0.02% 592
2023
Q4 		$32.1M Buy
243,935
+12,382
+5% +$1.43M 0.02% 603
2023
Q3 		$26M Sell
231,553
-10,951
-5% -$1.15M 0.02% 627
2023
Q2 		$22.9M Sell
242,504
-42,423
-15% -$4.15M 0.02% 684
2023
Q1 		$28.8M Buy
284,927
+877
+0.3% +$91.3K 0.02% 639
2022
Q4 		$33.9M Sell
284,050
-179
-0.1% -$21K 0.03% 595
2022
Q3 		$30.2M Buy
284,229
+1,189
+0.4% +$121K 0.02% 623
2022
Q2 		$27.6M Buy
283,040
+3,122
+1% +$288K 0.02% 671
2022
Q1 		$26.2M Sell
279,918
-15,126
-5% -$1.28M 0.02% 679
2021
Q4 		$25.1M Buy
295,044
+30,585
+12% +$2.81M 0.02% 684
2021
Q3 		$25.4M Sell
264,459
-5,727
-2% -$541K 0.02% 681
2021
Q2 		$26.3M Sell
270,186
-35,100
-11% -$3.36M 0.02% 690
2021
Q1 		$29.7M Sell
305,286
-1,208
-0.4% -$127K 0.02% 658
2020
Q4 		$29.4M Sell
306,494
-32,227
-10% -$3.11M 0.02% 655
2020
Q3 		$32.6M Sell
338,721
-87,124
-20% -$10.1M 0.02% 600
2020
Q2 		$52M Sell
425,845
-127,819
-23% -$14.1M 0.04% 481
2020
Q1 		$47.9M Buy
553,664
+256,002
+86% +$25.1M 0.04% 449
2019
Q4 		$32M Buy
+297,662
New +$31.2M 0.03% 603

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NBIX Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Neurocrine Biosciences (NBIX) stake by 2.3% in Q2 2026, selling an estimated $736K and leaving 215,488 shares worth $36.3M. The position accounts for 0.02% of the portfolio, ranked #533.

Sumitomo Mitsui Trust Group first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. The position peaked at $52M in Q2 2020. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 215,488 shares of Neurocrine Biosciences worth $36.3M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 4,961 Neurocrine Biosciences shares in Q2 2026, an estimated $736K.
  • Neurocrine Biosciences made up 0.02% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #533 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Sumitomo Mitsui Trust Group's Neurocrine Biosciences position peaked at $52M in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.